Shinpoong Pharmaceutical (019170) stock
KOSPI · Pharmaceuticals
As of the Nov 13 regular-session close (Korea)
- Market cap
- KRW 415.2 billion
- As of Nov 13, 2026
- P/E
- -509.27x
- Trailing twelve months
- P/B
- 1.49x
- Latest reported equity
- P/S
- 1.74x
- Trailing twelve months
- ROE
- -0.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- KRW 415.2 billion
- As of Nov 13, 2026
- P/E
- -509.27x
- Trailing twelve months
- P/B
- 1.49x
- Latest reported equity
- P/S
- 1.74x
- Trailing twelve months
- ROE
- -0.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-509.27x
Net loss — not comparable
P/B
1.49x
P/S
1.74x
Earnings and dividend metrics▾
Earnings
EPS
-KRW 16
Earnings per share
BPS
KRW 5,304
Book value per share
ROE
-0.3%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at KRW 16 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 5,304 of net assets.
- ROE — shareholder equity shrank by 0.3% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 63.9 billion | -KRW 8 billion | -KRW 8 billion | +9.0% |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 54.5 billion | -KRW 400 million | KRW 400 million | -1.6% |
| Q4 2025Consolidated · Filed Mar 20, 2026 | KRW 58 billion | KRW 3.9 billion | KRW 500 million | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 62.6 billion | KRW 7.2 billion | KRW 6.4 billion | +12.2% |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 58.6 billion | KRW 4.9 billion | KRW 2.8 billion | +4.6% |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 55.4 billion | -KRW 1.8 billion | -KRW 1.3 billion | +2.6% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 20, 2026 | KRW 234.7 billion | KRW 14.3 billion | KRW 8.4 billion | — |
| FY2024Consolidated · Filed Aug 14, 2025 | KRW 221.1 billion | -KRW 20.5 billion | -KRW 15.4 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 10.06%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 160 million
- Previous 20-day average 8.09%
- Net short position
- 1,389,213 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 3,931,787 shares
- As of Nov 13, 2026 · 7.50% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 10.06% | KRW 160 million |
| Nov 12, 2026 | 20.40% | KRW 330 million |
| Nov 11, 2026 | 11.53% | KRW 170 million |
| Nov 10, 2026 | 7.98% | KRW 110 million |
| Nov 9, 2026 | 9.69% | KRW 180 million |
| Nov 6, 2026 | 8.94% | KRW 210 million |
| Nov 5, 2026 | 10.18% | KRW 280 million |
| Nov 4, 2026 | 14.01% | KRW 440 million |
| Nov 3, 2026 | 6.93% | KRW 150 million |
| Nov 2, 2026 | 4.10% | KRW 80 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Material Management Information(Korean)Oct 22, 2026
- Material Management Information(Korean)Sep 15, 2026
- Results of Annual General Meeting(Korean)Mar 30, 2026 · Shareholders Meeting
- Resolution to Convene a Shareholders Meeting(Korean)Mar 10, 2026 · Shareholders Meeting
- [Amended] Change of 30% or More in Revenue or Profit Structure (15% for Large Companies)(Korean)Mar 10, 2026 · Preliminary Earnings
- [Amended] Decision on Acquisition of Shares in Another Company(Korean)Feb 27, 2026 · Investment
- Decision on Share Cancellation(Korean)Feb 26, 2026 · Share Cancellation
- Decision on Acquisition of Shares in Another Company(Korean)Feb 26, 2026 · Investment
Filings with a published English version open in English; the rest link to the Korean original.
Shinpoong Pharmaceutical (019170) stock information
KOSPI
Shinpoong Pharmaceutical (019170) is listed on KOSPI. Its market capitalization is about KRW 415.2 billion. On trailing-twelve-month earnings the P/E ratio is -509.27, and the P/B ratio is 1.49. Return on equity is -0.3%. These figures are computed in-house from official filings and are reference information only.
Shinpoong Pharmaceutical — frequently asked questions
- What is the P/E ratio of Shinpoong Pharmaceutical (019170)?
- On a trailing-twelve-month basis, 019170 trades at a P/E ratio of -509.27. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Shinpoong Pharmaceutical?
- 019170 has a market capitalization of about KRW 415.2 billion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.